Skip to main content
Equibles
XLO logo

XLO · Xilio Therapeutics, Inc. · Metrics

Track XLO — free

Use XLO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research XLO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$8.01 +0.00 (+0.00%)
Rebalance outlook locked
Market Cap
$44.47M
Shares
5.78M
Volume · Oct 28 6904 Avg daily vol (3M) 12.97K

XLO metrics

65 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$8.01
Market cap
$44.47M

Price action

20 metrics
Price change (1W)
-6.2%
Price change (30D)
-11.5%
Price change (3M)
-12.5%
Price change (6M)
+1.1%
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
42.0%
Annualized volatility (3M)
32.5%
Beta
0.7
RSI (14D)
39.7
Price vs SMA 50
-9.9%
Price vs SMA 200
—
Avg volume (3M)
12,972
Relative volume
2.2
Average dollar volume
$115,144

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
5.78M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
-1.4×
EV / EBITDA
—
EV / EBIT
—
P / sales
0.7×
reciprocal yield 144.1%
P / book
0.6
reciprocal yield 162.5%
FCF yield
-137.8%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-49.1%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
-2.8×
EV / revenue historical average (5Y)
-2.8×
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2025-11-13

Profitability

9 metrics
Gross margin
—
Operating margin
-48.9%
Trailing 12 months
Net margin
-34.1%
Gross profit (TTM)
—
Operating profit (TTM)
−$31.37M
Net income (TTM)
−$21.83M
Trailing 12 months
Diluted EPS (TTM)
$-0.31
FCF margin
-95.6%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$10.98

Growth

11 metrics
Revenue growth YoY
+131.2%
Year over year
Net income growth YoY
—
Revenue (TTM)
$64.09M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+38.6%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-30.2%
Return on assets
-14.2%
Debt / equity
0.0
Current ratio
4.3
EBITDA (TTM)
−$30.03M
Free cash flow (TTM)
−$61.27M
Quick ratio
4.3
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$136.04M
Latest balance sheet
Cash & equivalents
$136.04M
Total assets
$154.25M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$60.60M
Capital expenditures (TTM)
$670,000
R&D (TTM)
$66.83M
SG&A (TTM)
—
Stock compensation (TTM)
$7.86M
R&D / revenue
104.3%
Stock compensation / revenue
12.3%

Ownership (13F)

9 metrics
13F filers
27
13F filer change QoQ
+3
Institutional ownership
58.9%
Conviction holders (share of 13F filers)
3.7%
Crowding (high-turnover and private-fund holders)
28.8%
Private-fund adviser ownership
26.2%
Active holders' share change QoQ
+33.8%
Holder tenure
7.3
Price vs estimated holder cost
-0.5%

Ownership (registered funds)

1 metrics
Index-fund ownership
3.8%

Short interest

3 metrics
Short interest
6.9%
Latest settlement · 41.2 days to cover
Days to cover
41.2d
Short-squeeze score
66 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1840233 CUSIP 98422T209 Visit website Investor relations